Oryzon Genomics S.A.

BMV:ORY N Stock Report

Market Cap: Mex$2.3b

Oryzon Genomics Management

Management criteria checks 2/4

Oryzon Genomics' CEO is Carlos Manuel Buesa Arjol, appointed in Jan 2000, has a tenure of 23.42 years. directly owns 6.35% of the company’s shares, worth MX$146.88M. The average tenure of the management team and the board of directors is 2.4 years and 7.6 years respectively.

Key information

Carlos Manuel Buesa Arjol

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure23.4yrs
CEO ownership6.4%
Management average tenure2.4yrs
Board average tenure7.6yrs

Recent management updates

No updates

Recent updates

CEO

Carlos Manuel Buesa Arjol

23.4yrs

Tenure

US$62,992

Compensation

Dr. Carlos Manuel Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advi...

Leadership Team

NamePositionTenureCompensationOwnership
Carlos Manuel Buesa Arjol
Co-Founder23.4yrsUS$62.99k6.35%
MX$ 146.9m
Enric Condomines
Director of Operations3yrsno datano data
Jordi Pey
Chief Scientific Officer2.4yrsno datano data
Xavier Ribera
Head of Internal Audit & Complianceno datano datano data
Emili Cortada
Chief Business Development Officerno datano datano data
Neus Bernado
Chief Intellectual Property Officer11.8yrsno datano data
Michael Ropacki
Chief Medical Officer of CNS2.4yrsno datano data
Sonia Paloma Bezon
Chief of Clinical Operations5.7yrsno datano data
Saikat Nandi
Global Chief Business Officer1.6yrsno datano data
Ana Limon
Senior Vice President of Clinical Development & Global Medical Affairs1.4yrsno datano data
Douglas Faller
Global Chief Medical Officer1.3yrsno datano data
Augusto Pinel Rubio
Secretaryno datano datano data

2.4yrs

Average Tenure

Experienced Management: ORY N's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Carlos Manuel Buesa Arjol
Co-Founder22.4yrsUS$62.99k6.35%
MX$ 146.9m
Howard Fillit
Member of Scientific Advisory Boardno datano datano data
Isabel Navarro
Independent Director7.6yrsUS$7.60kno data
Lori Kunkel
Member of Scientific Advisory Board5.3yrsno datano data
Manuel López-Figueroa
Lead Independent Director3.1yrsno datano data
Josep Maria Echarri Torres
Director21.3yrsUS$6.52k1.86%
MX$ 43.0m
Tamara Maes
VP of the Board & President of Scientific Advisory Board23.4yrsUS$62.99k4.51%
MX$ 104.3m
Ramon Adell Ramon
Independent Director7.6yrsUS$7.60k0.040%
MX$ 929.7k
Leon Hooftman
Member of Scientific Advisory Boardno datano datano data
Antonio Fornieles Melero
Independent Director7.6yrsUS$7.60kno data
Felipe Prosper Cardoso
Member of Scientific Advisory Boardno datano datano data
Jose Luis Molinuevo
Member of Scientific Advisory Boardno datano datano data

7.6yrs

Average Tenure

65yo

Average Age

Experienced Board: ORY N's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/13 03:31
End of Day Share Price 2023/03/16 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oryzon Genomics S.A. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arron AatkarEdison Investment Research
Joaquin Garcia-QuirosJB Capital Markets
Lucy-Emma Mary Codrington-BartlettJefferies LLC